Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

Boehringer Ingelheim (BI) and Click Therapeutics have ... that will provide additional treatment options to those living with schizophrenia. The novel mobile application combines multiple ...

Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce ...

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...

The lifetime risk of an unexpected and sudden death from a cardiovascular cause in the absence of pre-existing heart disease—known as sudden cardiac death—is more than 4 times higher for people with ...

The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.

Prescription digital therapeutics for mental health have the potential to increase patient access to care, but major barriers ...

Researchers Discover a Mechanism That Impairs Synaptic Plasticity in the Brains of Schizophrenia Patients Sep. 4, 2024 — A study mapped genes linked to schizophrenia and uncovered a mechanism ...